

01/12/2016



**3rd ESH INTERNATIONAL CONFERENCE ON  
NEW CONCEPTS IN LYMPHOID MALIGNANCIES:  
Focus on CLL and Indolent Lymphoma**

Mandelieu Congress Center, Mandelieu, France  
September 15-17, 2017

Chairs: Michael Hallek, Stephan Stilgenbauer, Louis Staudt, Andrei Thomas-Tikhonenko

**Friday, September 15, 2017**

**08:00–08:15**     **Welcome**

**SESSION I – BIOLOGY 1**

**Chair: TBA**

- |             |  |                                  |
|-------------|--|----------------------------------|
| 08:15-08:35 | Pathways of B-cell differentiation and lymphoid cancer   | Jason Cyster (San Francisco)*    |
| 08:35-08:40 | <i>Discussion</i>  |                                  |
| 08:40-09:00 | Genomic landscape of CLL and other indolent lymphoma   | Cathy Wu (Boston)                |
| 09:00-09:05 | <i>Discussion</i>  |                                  |
| 09:05-09:25 | Routes of transformation of follicular lymphoma  | Jude Fitzgibbon (London)         |
| 09:25-09:30 | <i>Discussion</i>  |                                  |
| 09:30-09:50 | Mechanism of lymphoma progression  | Riccardo Dalla-Favera (New York) |
| 09:50-09:55 | <i>Discussion</i>  |                                  |
| 09:55-10:25 | <b><i>Oral presentations selected from submitted abstracts and/or Round table or controversial debates</i></b> |                                  |

**10:25-11:00**     **Coffee Break**

**SESSION II – BIOLOGY 2**

**Chair: TBA**

- |             |  |                            |
|-------------|--|----------------------------|
| 11:00-11:20 | B Cell-receptor signaling  | Michael Reth (Freiburg)*   |
| 11:20-11:25 | <i>Discussion</i>  |                            |
| 11:25-11:45 | CLL microenvironment as a drug target for kinase inhibitors  | Jan Burger (Houston)       |
| 11:45-11:50 | <i>Discussion</i>  |                            |
| 11:50-12:10 | Mechanisms of BCR signaling in lymphoma  | Louis Staudt (Bethesda)    |
| 12:10-12:15 | <i>Discussion</i>  |                            |
| 12:15-12:35 | Modulation of the TME in NHL   | Adrian Wiestner (Bethesda) |
| 12:35-12:40 | <i>Discussion</i>  |                            |
| 12:40-13:20 | <b><i>Oral presentations selected from submitted abstracts and/or Round table or controversial debates</i></b> |                            |

**13:20-14:50**      *Lunch*

**13:50-14:50**      **Possible slot for a SATELLITE SYMPOSIUM**

**SESSION III – BIOLOGY 3**

**Chair: TBA**

14:50-15:10	Epigenetics of lymphoid malignancies	Laura Pasqualucci (New York)
15:10-15:15	<i>Discussion</i>	
15:15-15:35	Epigenetics of lymphoid malignancies	Ari Melnick (New York)
15:35-15:40	<i>Discussion</i>	
15:40-16:00	DNA damage response in lymphoid malignancies	Christian Reinhardt (Cologne)
16:00-16:05	<i>Discussion</i>	
16:05-16:25	Splicing defects (SF3B1) in lymphoid malignancies	Omar Abdel Wahab (New York)
16:25-16:30	<i>Discussion</i>	
16:30-16:50	Cell cycle regulation	Selena Chen Kiang (New York)
16:50-16:55	<i>Discussion</i>	
16:55-17:25	<b><i>Oral presentations selected from submitted abstracts and/or Round table or controversial debates</i></b>	

**17:25-17:55**      *Coffee break*

**SESSION IV – IMPACT OF CURRENT AND FUTURE STRATEGIES ON REIMBURSEMENT POLICY.  
DISPARITY OF CLL AND LYMPHOMA TREATMENT IN EUROPE AND THE WORLD**

**Chair: TBA**

17:55-18:15	TBA	Jackson Orem (Uganda)*
18:15-18:20	<i>Discussion</i>	
18:20-18:40	TBA	TBA
18:40-18:45	<i>Discussion</i>	
18:45-19:05	TBA	Speaker TBA
19:05-19:10	<i>Discussion</i>	
19:10-19:40	Round Table	

**Saturday, September 16, 2017**

**08:00-09:30**      **Possible slot for a SATELLITE SYMPOSIUM**

**08:30-09:30**      **3 Meet the Expert sessions**

**09:30-09:45**      *Coffee break*

**SESSION V – BIOLOGY 4: MOLECULAR DIAGNOSTICS AND DISEASE ASSESSMENT IN LYMPHOMA**

**Chair: TBA**

09:45-10:05	MRD in CLL	Andy Rawstron (Leeds)*
10:05-10:10	<i>Discussion</i>	

10:10-10:30	MRD, circulating tumour DNA in NHL	Ash Alizadeh (Palo Alto)
10:30-10:35	<i>Discussion</i>	
10:35-10:55	Diagnostic work up and genomics in CLL	Stephan Stilgenbauer (Ulm)
10:55-11:00	<i>Discussion</i>	
11:00-11:20	Initial diagnostic work up of MCL	Martin Dreyling (Munich)
11:20-11:25	<i>Discussion</i>	
11:25-11:45	Initial diagnostic work up of follicular lymphoma, others	TBA
11:45-11:50	<i>Discussion</i>	
11:50-13:00	Lunch	

## **SESSION VI – CELLULAR AND OTHER IMMUNOTHERAPIES FOR INDOLENT LYMPHOID MALIGNANCIES**

**Chair: TBA**

13:00-13:20	CART in indolent NHL	Carl June (Philadelphia)
13:20-13:25	<i>Discussion</i>	
13:25-13:45	Novel bispecific antibodies	Ralf Bargou (Würzburg)
13:45-13:50	<i>Discussion</i>	
13:50-14:10	Status of allogeneic transplant immunotherapy	David Maloney (Seattle)
14:10-14:15	<i>Discussion</i>	
14:15-14:35	Checkpoint inhibitors	Stephen Ansell (Rochester)
14:35-14:40	<i>Discussion</i>	
14:40-15:00	Mechanisms of resistance to immunotherapies	Andrei Thomas-Tikhonenko (Philadelphia)
15:00-15:05	<i>Discussion</i>	
14:50-15:20	<i>Selected oral presentations and/or Round table or controversial debates</i>	
<b>15:20-15:50</b>	<b><i>Coffee Break</i></b>	

## **SESSION VII – UPDATE ON NOVEL AGENTS IN NHL**

**Chair: TBA**

15:50-16:10	BCL2 & regulation of the apoptotic response in lymphoid malignancies	Antony Letai (Boston)
16:10-16:15	<i>Discussion</i>	
16:15-16:35	Regulation of Mcl1, BCL2 and other regulators of apoptosis as druggable targets	TBA
16:35-16:40	<i>Discussion</i>	
16:40-17:00	BCL2 inhibitors, up date on clinical development	Andrew W. Roberts (Parkville)
17:00-17:05	<i>Discussion</i>	
17:05-17:25	BTK inhibitors	TBA
17:25-17:30	<i>Discussion</i>	
17:30-17:50	PI3K inhibitors	Gilles Salles (Lyon)

17:50-17:55 *Discussion*

17:55-18:15 Open slot

18:15-18:20 *Discussion*

18:20-18:50 *Selected oral presentations and/or Round table or controversial debates*

**19:00-20:30 *Manned Poster Session with refreshments***

## Sunday, September 17, 2017

### 07:30-08:30 3 Simultaneous Meet the Expert Sessions

#### SESSION VIII – STATE OF THE ART TREATMENT AND STRATEGIES OF INTERNATIONAL STUDY GROUPS TO INTEGRATE GENOMICS, NOVEL AGENTS AND TRADITIONAL APPROACHES INTO ONE TREATMENT CONCEPT

Chair: TBA

08:45-09:05	Lysa	Gilles Salles (Lyon)
09:05-09:10	<i>Discussion</i>	
09:10-09:30	DCLLSG	Michael Hallek (Cologne)
09:30-09:35	<i>Discussion</i>	
09:35-09:55	GIMEMA - FIL	Robin Foà (Rome)
09:55-10:00	<i>Discussion</i>	
10:00-10:30	Coffee Break	
10:30-10:50	Indolent lymphoma trials in the US (ECOG)	Richard Little (Bethesda)
10:50-10:55	<i>Discussion</i>	
10:55-11:15	European Mantle Cell Network	Martin Dreyling (Munich)
11:15-11:20	<i>Discussion</i>	
11:20-11:40	UK National lymphoma group	Simon Rule (Plymouth)
11:40-11:45	<i>Discussion</i>	
11:45-12:15	<i>Round Table</i>	

#### MEETING CLOSURE

\* Speakers pending confirmation